TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT03340506: Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study

Sponsor: Novartis Pharmaceuticals · Phase: PHASE4 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$443,520

Rescue Site Savings

+$295,680

Unlock Full NCT03340506 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03340506 Rescue Dossier →